b.) Amendments to the Claims

1. (Currently Amended) A cyclic peptide, or a pharmaceutically acceptable salt thereof, having an activity to restore DNA-binding activity or P53 protein-dependent transcription activity to mutant P53 protein, said peptide being represented by formula (I): $R^{1}(X^{1})^{nl}(X^{2})^{n2}(X^{3})^{n3}(X^{4})^{n4}(X^{5})^{n5}(X^{6})^{n6}(X^{7})^{n7}(X^{8})^{n8}(X^{9})^{n9}(X^{10})^{n10}(X^{11})^{n11}(X^{12})^{n12}$ $(X^{13})^{n13}(X^{14})^{n14}(X^{15})^{n15}(X^{16})^{n16}(X^{17})^{n17}R^{2}$ (I) wherein

any of X^1 to X^{17} may be denoted by X^i , i being an integer of 1 to 17; any of nl to n17 may be denoted by ni, where ni represents 0 or 1 such that $(X^i)^{ni}$ represents X^i when ni is 1 and represents a bond when ni is 0;

ni represents 1 for at least 7 different X^i s, with R^1 bonded to the N-terminus and R^2 bonded to the C-terminus:

any of X^1 to X^{11} where ni represents 1 may be denoted by X^p and any of X^8 to X^{17} where ni represents 1 may be denoted by X^q such that q > p; to represent one sequence, in which a functional group in residue X^p (where p is an integer of 1 to 11) and a functional group in residue X^q (where q is an integer of 8 to 17, provided that q is larger than p) together form a cyclic structure;

R¹ represents substituted or unsubstituted alkanoyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aralkyloxycarbonyl, substituted or unsubstituted aroyl, 9-fluorenylmethoxycarbonyl or hydrogen;

R² represents substituted or unsubstituted alkoxy, substituted or

 \mathcal{D}_{I}

unsubstituted aralkyloxy, amino, substituted or unsubstituted alkylamino, substituted or unsubstituted dialkylamino, substituted or unsubstituted aralkylamino, substituted or unsubstituted arylamino or hydroxy;

R¹ and R² may together form a single bond when the total number of amino acid and organic acid residues having an SH group in the peptide is two or less, or a functional group in X^p and a functional group in X^q may together form a covalent bond to form a cyclic structure together with any intervening Xⁱ residues;

X¹ represents a residue of 2-mercaptobenzoic acid, 3-mercaptopropionic acid, 4-mercaptobutanoic acid, mercaptoacetic acid, adipic acid, suberic acid, cysteine, homocysteine, penicillamine, aspartic acid, glutamic acid, homoglutamic acid, isoaspartic acid, isoglutamic acid, 2-aminoadipic acid, 2-aminosuberic acid, ornithine, lysine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, p-aminophenylalanine, serine, threonine, homoserine, α-methylserine, 3-hydroxyproline or 4-hydroxyproline;

 X^2 represents a residue of leucine, isoleucine, valine, alanine, norvaline, norleucine, 2-aminobutanoic acid, homoleucine, β -alanine, α -aminoisobutanoic acid, β -cyclopropylalanine, β -chloroalanine, 1-aminocyclopentane-1-carboxylic acid, 1-amino-1-cyclohexanecarboxylic acid, 2-amino-1-cyclopentanecarboxylic acid, t-butylglycine, diethylglycine, t-butylalanine, O-methylserine, cyclohexylglycine, cyclohexylalanine or glycine;

 X^3 represents a residue of lysine arginine, ornithine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, p-aminophenylalanine or glycine; X^4 represents a residue of serine, threonine, homoserine, α -



methylserine, 3-hydroxyproline, 4-hydroxyproline, cysteine, homocysteine, penicillamine, aspartic acid, glutamic acid, homoglutamic acid, isoaspartic acid, isoglutamic acid, 2-aminoadipic acid, 2-aminosuberic acid, ornithine, lysine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, p-aminophenylalanine, glycine, 2-mercaptobenzoic acid, 3-mercaptopropionic acid, 4-mercaptobutanoic acid, mercaptoacetic acid, adipic acid or suberic acid;

X⁵ represents a residue of lysine, arginine, ornithine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, p-aminophenylalanine or glycine;

X⁶ represents a residue of lysine, arginine, ornithine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, p-aminophenylalanine or glycine;

X⁷ represents a residue of alanine, β-alanine, 2-aminobenzoic acid, 3-aminobenzoic acid, 4-aminobenzoic acid, 3-aminomethylbenzoic acid, proline, 3-hydroxyproline, 4-hydroxyproline, L-1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid, cysteine, homocysteine, penicillamine, 2,3-diaminopropionic acid, 2,4-diaminobutanoic acid, ornithine, lysine, p-aminophenylalanine, aspartic acid, glutamic acid, isoaspartic acid, isoglutamic acid, 2-aminoadipic acid, 2-aminosuberic acid or glycine;

X⁸ represents a residue of glutamine, asparagine, cysteine, homocysteine, penicillamine, aspartic acid, glutamic acid, homoglutamic acid, isoaspartic acid, isoglutamic acid, 2-aminoadipic acid, 2-aminosuberic acid, ornithine, lysine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, p-aminophenylalanine, serine, threonine, homoserine, α-methylserine, 3-hydroxyproline, 4-hydroxyproline, glycine, 2-mercaptobenzoic acid, 3-mercaptopropionic acid, 4-mercaptobutanoic acid, mercaptoacetic



acid, adipic acid or suberic acid;

X⁹ represents a residue of serine, threonine, homoserine, α-methylserine, 3-hydroxyproline, 4-hydroxyproline, cysteine, homocysteine, penicillamine, aspartic acid, glutamic acid, homoglutamic acid, isoaspartic acid, isoglutamic acid, 2-aminoadipic acid, 2-aminosuberic acid, ornithine, lysine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, p-aminophenylalanine, glycine, 2-mercaptobenzoic acid, 3-mercaptopropionic acid, 4-mercaptobutanoic acid, mercaptoacetic acid, adipic acid or suberic acid;

X¹⁰ represents a residue of serine, threonine, homoserine, αmethylserine, hydroxyproline, cysteine, homocysteine, penicillamine, aspartic acid,
glutamic acid, homoglutamic acid, isoaspartic acid, isoglutamic acid, 2-aminoadipic acid,
2-aminosuberic acid, ornithine, lysine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic
acid, p-aminophenylalanine, glycine, 2-mercaptobenzoic acid, 3-mercaptopropionic acid,
4-mercaptobutanoic acid, mercaptoacetic acid, adipic acid or suberic acid;

X¹¹ represents a residue of serine, threonine, homoserine, α-methylserine, hydroxyproline, cysteine, homocysteine, penicillamine, aspartic acid, glutamic acid, homoglutamic acid, isoaspartic acid, isoglutamic acid, 2-aminoadipic acid, 2-aminosuberic acid, ornithine, lysine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, p-aminophenylalanine, glycine, 2-mercaptobenzoic acid, 3-mercaptopropionic acid, 4-mercaptobutanoic acid, mercaptoacetic acid, adipic acid or suberic acid;

X¹² represents a residue of lysine, arginine, ornithine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, p-aminophenylalanine or glycine;



D

X¹³ represents a residue of histidine, alanine, 4-thiazolylalanine, 2-thienylalanine, 2-pyridylalanine, 3-pyridylalanine, 4-pyridylalanine, (3-N-methyl)piperidylalanine, 3-(2-quinoyl)alanine, serine, threonine, homoserine, α-methylserine, 3-hydroxyproline, 4-hydroxyproline, cysteine, homocysteine, penicillamine, aspartic acid, glutamic acid, homoglutamic acid, isoaspartic acid, isoglutamic acid, 2-aminoadipic acid, 2-aminosuberic acid, ornithine, lysine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, p-aminophenylalanine or glycine;

 X^{14} represents a residue of lysine, arginine, ornithine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, p-aminophenylalanine, serine, threonine, homoserine, α -methylserine, 3-hydroxyproline, 4-hydroxyproline, cysteine, homocysteine, penicillamine, aspartic acid, glutamic acid, homoglutamic acid, isoaspartic acid, isoglutamic acid, 2-aminoadipic acid, 2-aminosuberic acid or glycine, and an amino group or guanidino group in the side chain of X^{14} may be modified with R^3 (where R^3 is independently selected from the moieties of R^1 ;

X¹⁵ represents lysine, arginine, ornithine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, p-aminophenylalanine or glycine;

 X^{16} represents a residue of leucine, alanine, 4-thiazolylalanine, 2-thienylalanine, isoleucine, norleucine, homoleucine, valine, norvaline, β -alanine, α -aminoisobutanoic acid, 2-aminobutanoic acid, β -cyclopropylalanine, β -chloroalanine, 1-aminocyclopentane-1-carboxylic acid, 1-amino-l-cyclohexanecarboxylic acid, 2-amino-1-cyclopentanecarboxylic acid, t-butylglycine, diethylglycine, t-butylalanine, O-methylserine, cyclohexylglycine, cyclohexylalanine or glycine;

X¹⁷ represents a residue of 2-mercaptoaniline, cysteamine, homocysteamine, cysteine, homocysteine, penicillamine, ornithine, lysine, 2,3-diaminopropionic acid, 2,4-diaminobutanoic acid, p-aminophenylalanine, glutamic acid, aspartic acid, homoglutamic acid, isoaspartic acid, isoglutamic acid, 2-aminoadipic acid or 2-aminosuberic acid; and

R²-represents substituted or unsubstituted alkoxy, substituted or unsubstituted aralkyloxy, amino, substituted or unsubstituted alkylamino, substituted or unsubstituted aralkylamino, substituted or unsubstituted aralkylamino, substituted or unsubstituted aralkylamino, substituted or unsubstituted arylamino or hydroxy;

where organic acid or amino acid residues independently selected from X[†] to X^{††} may be deleted, substituted or added, or a 12-aminododecanoic acid residues may be substituted or added at the N- or C- terminus of the petpide, provided that at least seven X[†]s where ni=1 remain.

- 2. (Previously Amended) A peptide or a pharmaceutically acceptable salt thereof according to claim 1, wherein said cyclic structure is formed by a S-S, S-CH₂-S, S-CH₂-C₆H₄-CH₂-S, S-CH₂-CO, CO-NH, NH-CO, O-CO or CO-O bond between X^P and X^Q .
- 3. (Previously Amended) A peptide or a pharmaceutically acceptable salt thereof according to claim 2, wherein X^{p} (np=1) is an N-terminal residue and X^{q} (nq=1) is a C-terminal residue.

- 4. (Previously Amended) A peptide or a pharmaceutically acceptable salt thereof according to claim 2, wherein X^{p} (np=1) is not an N-terminal residue and X^{q} (nq=1) is not a C-terminal residue.
- 5. (Previously Amended) A peptide or a pharmaceutically acceptable salt thereof according to claim 2, wherein X^{P} (np=1) is not an N-terminal residue and X^{q} (nq=1) is a C-terminal residue.
- 6. (Previously Amended) A peptide or a pharmaceutically acceptable salt thereof according to claim 2, wherein X^{P} (np=1) is an N-terminal residue and X^{q} (nq=1) is not a C-terminal residue.
- 7. (Previously Amended) A peptide or a pharmaceutically acceptable salt thereof according to claim 3, wherein X^p (np=1) is X^1 and X^q (nq=1) is X^{17} .
- 8. (Previously Amended) A peptide or a pharmaceutically acceptable salt thereof according to claim 6, wherein X^{p} (np=1) is X^{1} and X^{q} (nq=1) is X^{17} .
- 9. (Previously Amended) A peptide or a pharmaceutically acceptable salt thereof according to claim 3, wherein X^{P} (np=1) is X^{I} and X^{Q} (nq=1) is X^{I6} .
 - 10. (Previously Amended) A peptide or a pharmaceutically acceptable salt



thereof according to claim 6, wherein X^{P} (np=1) is an N-terminal residue and X^{Q} (nq=1) is X^{R} .

- 11. (Previously Amended) A peptide or a pharmaceutically acceptable salt thereof according to claim 4, wherein X^P (np=1) is X^8 and X^q (nq=1) is X^{14} .
- 12. (Previously Amended) A peptide or a pharmaceutically acceptable salt thereof according to claim 5, wherein X^P (np=1) is X^3 and X^q (nq=1) is a C-terminal residue.
- 13. (Previously Amended) A peptide or a pharmaceutically acceptable salt thereof according to claim 4, wherein X^P (np=1) is X^3 and X^q (nq=1) is not a C-terminal residue.
- 14. (Previously Amended) A peptide or a pharmaceutically acceptable salt thereof according to claim 6, wherein X^P (np=1) is an N-terminal residue and X^q (nq=1) is X^{11} .
- 15. (Currently Amended) A peptide or a pharmaceutically acceptable salt thereof according to claim 1, said peptide having an amino acid sequence shown by one of SEQ ID NOS: 4-7 and 16-32 in which one to several organic acid or amino acid residues independently selected from X[†]-to X^{††}-may be deleted, substituted or added, or a 12-

-11-

aminododecanoic acid residues may be substituted or added at the – or C- terminus of the peptide.

16. (Currently Amended) A peptide or a pharmaceutically acceptable salt thereof according to claim 15, said peptide having an amino acid sequence shown by one of SEQ ID NOS: 4-7, 16, 19 and 25-32 in which one to several organic acid or amino acid residues independently selected from X[†] to X^{††} may be deleted, substituted or added, or a 12-aminododecanoic acid residues may be substituted or added at the – or C- terminus of the petpide.

